Ignite Creation Date:
2025-12-25 @ 1:20 AM
Ignite Modification Date:
2026-02-02 @ 6:50 PM
Study NCT ID:
NCT01810393
Status:
COMPLETED
Last Update Posted:
2020-09-04
First Post:
2013-03-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-06-11
Start Date Type:
ACTUAL
Primary Completion Date:
2019-07-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-07-17
Completion Date Type:
ACTUAL
First Submit Date:
2013-03-11
First Submit QC Date:
None
Study First Post Date:
2013-03-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-09-03
Last Update Post Date:
2020-09-04
Last Update Post Date Type:
ACTUAL